[go: up one dir, main page]

WO2018163202A1 - Formulations de dronabinol stables - Google Patents

Formulations de dronabinol stables Download PDF

Info

Publication number
WO2018163202A1
WO2018163202A1 PCT/IN2018/050117 IN2018050117W WO2018163202A1 WO 2018163202 A1 WO2018163202 A1 WO 2018163202A1 IN 2018050117 W IN2018050117 W IN 2018050117W WO 2018163202 A1 WO2018163202 A1 WO 2018163202A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
dronabinol
stable
solution
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2018/050117
Other languages
English (en)
Inventor
Teresa BANDROWSKY
Laxman SHINDE
Yogesh RANE
Girish Kumar Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkem Laboratories Ltd
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of WO2018163202A1 publication Critical patent/WO2018163202A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the present invention relates to formulations of cannabinoids such as dronabinol. BACKGROUND
  • Delta-9-Tetrahydrocannabinol (also known as THC, dronabinol and D9THC) is a naturally occurring compound and is the primary active ingredient in the controlled substance marijuana.
  • Marijuana refers to the dried flowers and leaves of Cannabis Sativa, the hemp plant. These parts of the plant contain several compounds called cannabinoids (including dronabinol), that may help patients with certain disease conditions.
  • Dronabinol has been approved by the Food and Drug Administration (FDA) for the control of nausea and vomiting associated with chemotherapy and, more recently, for appetite stimulation of AIDS patients suffering from wasting syndrome.
  • FDA Food and Drug Administration
  • Synthetic dronabinol has been utilized as a pharmaceutically active ingredient, and cannabis-based medicines using botanical sources of cannabis rather than synthetic THC are also known in the art.
  • Lipophilic compounds that are unstable in the presence of oxygen and moisture such as dronabinol, have proven difficult to formulate into stable aqueous-based formulations due to degradation and insolubility.
  • U.S. Pat. No. 6,747,058 describes an aerosolizable formulation for delivery of delta-9- tetrahydrocannabinol in a semi-aqueous solvent, such as 35: 10:55 alcohol :water:propylene glycol (v/v), which is said to produce a stable clear solution near the solubility point of the drug.
  • a semi-aqueous solvent such as 35: 10:55 alcohol :water:propylene glycol (v/v)
  • v/v alcohol :water:propylene glycol
  • liquid cannabinoid formulations contain between about 25% to about 35%) w/w water; more preferably, between about 30%> and about 33%> w/w water, and most preferably, about 33%> w/w water.
  • the said invention describes the liquid cannabinoid formulations comprising dronabinol and, the following ingredients 25-33%) w/w water, combination of propylene glycol & polyethylene glycol, alcohol, butylated hydroxyanisole, and preservative such as paraben.
  • It is a further object of the invention to provide a stable pharmaceutical formulations comprising from about 0.1 to about 5% w/w dronabinol, at least about 40% w/w or more of water, buffered to a pH from about 6 to about 7.5, from about 15 to about 65% w/w alcohol, from about 3 to about 10 % w/w propylene glycol, from about 0.001 to about 1% w/w butylated hydroxyanisole, wherein the formulation does not use polyethylene glycol, and wherein the formulation is stable at 5 °C, and/or; 25 °C /60% RH and/or 40 °C/75%.
  • It is a further object of the invention to provide stable oral solutions comprising a cannabinoid, preferably, dronabinol from about 0.1 to 5% w/w, and the following ingredients: a) at least about 40% w/w or more of water, buffered to a pH of 6-7.5, b) about 50% w/w alcohol, c) about 3-10 % w/w propylene glycol, d) about 0.01% w/w butylated hydroxylanisole (BHA), wherein the formulation is stable at 5 °C, and/or; 25 °C /60% RH and/or 40 °C/75%.
  • a cannabinoid preferably, dronabinol from about 0.1 to 5% w/w
  • the following ingredients a) at least about 40% w/w or more of water, buffered to a pH of 6-7.5, b) about 50% w/w alcohol, c) about 3-10 % w/w propylene glycol
  • It is a further object of the invention to provide stable oral solution of dronabinol comprising of about 0.54%) w/w dronabinol, about 42% w/w water, buffered to a pH of 6-7.5, about 50% w/w alcohol, about 5.7 % w/w propylene glycol, about 1.8% w/w sucralose, and about 0.015% w/w butylated hydroxyanisole (BHA), wherein said oral solution is stable at 5 °C, and/or; 25 °C /60% RH and/or 40 °C/75%.
  • stable or “stability” as used herein with respect to dronabinol refers to a dronabinol formulation that contains at least about 80% w/w and preferably at least about 90% w/w of the dronabinol in undegraded form after exposure of the formulation at 5 °C, for at least 6 to 12 months and/or; 25 °C /60% RH for at least 6 months; and/or 40 °C/75% RH for at least 3 to 6 months.
  • the invention may be summarized as given below:
  • a stable pharmaceutical formulation comprising from about 0.1 to about 5% w/w dronabinol, at least about 40% w/w or more of water buffered to a pH from about 6 to about 7.5, from about 15 to about 65%) w/w alcohol, from about 3 to about 10 %> w/w propylene glycol, from about 0.001 to about 1%> w/w butylated hydroxyanisole, wherein the formulation does not use polyethylene glycol, and wherein the formulation is stable at 5 °C, for at least 6 to 12 months and/or; 25 °C /60% RH for at least 6 months ; and/or 40 °C/75% RH for at least 3 to 6 months.
  • a stable oral pharmaceutical solution comprising of about 0.54%> w/w dronabinol, about 42%> w/w water, buffered to a pH of 6-7.5, about 50%> w/w alcohol, about 5.7 %> w/w propylene glycol, about 1.8% w/w sucralose, and about 0.015%> w/w butylated hydroxyanisole, wherein the solution does not use polyethylene glycol, and wherein said oral solution is stable at 5 °C, for at least 6 to 12 months and/or; 25 °C /60% RH for at least 6 months ; and/or 40 °C/75% RH for at least 3 to 6 months.
  • Dronabinol is unstable in the presence of oxygen and moisture resulting in rapid degradation. Additionally, dronabinol demonstrates low solubility in water, 2.8 mg/L at 23°C. Issues associated with degradation and insolubility makes formulating dronabinol into a stable solution challenging.
  • the proposed dronabinol formulation of the present invention represents a liquid formulation with the highest water content to date to achieve chemical stability at 5 °C, and/or; 25 °C /60% RH and/or 40 °C/75%.
  • the formulation of the invention comprises stable oral pharmaceutical formulations comprising from about 0.1 to about 5% w/w dronabinol, at least about 40% w/w or more of water, buffered to a pH from about 6 to about 7.5, from about 15 to about 65% w/w alcohol, from about 3 to about 10 % w/w propylene glycol, from about 0.001 to about 1% w/w butylated hydroxyanisole, wherein the formulations do not use polyethylene glycol.
  • the dronabinol formulation is stable at 5 °C, for at least 6 to 12 months and/or; 25 °C /60% RH for at least 6 months; and/or 40 °C/75% RH for at least 3 to 6 months.
  • the formulation may be stored in a refrigerator or at ambient temperatures and humidity.
  • Cannabinoids in general, and dronabinol specifically, are insoluble in water.
  • the formulations of the present invention is an aqueous - based 1 pharmaceutical formulation of dronabinol using the high water content wherein said oral pharmaceutical formulation is stable at 5 °C, and/or; 25 °C /60% RH and/or 40 °C/75%. Additionally the composition is free from any preservative.
  • cannabinoid includes naturally occurring and non-natural derivatives of cannabinoids which can be obtained by derivation of natural cannabinoids and which are unstable like natural cannabinoids.
  • the cannabinoid used in the formulations of the invention may be natural, semi-synthetic, or synthetic.
  • the cannabinoid may be included in its free form, or in the form of a salt; an acid addition salt of an ester; an amide; an enantiomer; an isomer; a tautomer; a prodrug; a derivative of an active agent of the present invention; different isomeric forms (for example, enantiomers and diastereoisomers), both in pure form and in admixture, including racemic mixtures; enol forms.
  • cannabinoid is also meant to encompass derivatives that are produced from another compound of similar structure by the replacement of, e.g., substitution of one atom, molecule or group by another such as 1 l-hydroxy-delta-8- tetrahydrocannabinol and 1 l-hydroxy-delta-9-tetrahydrocannabinol.
  • cannabinoid further includes delta-8- tetrahydrocannabinol, delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, nabilone, delta-9-tetrahydro cannabinotic acid, the non-psychotropic cannabinoid 3- dimethylnepty 11 carboxylic acid homologine 8. (J. Med. Chem. 35, 3135, 1992).
  • cannabinoid also includes prodrugs of cannabinoids, as well as pharmaceutically acceptable salts and complexes of cannabinoids.
  • An example of a suitable prodrug is THC- hemi succinate.
  • Dronabinol is naturally-occurring and has been extracted from Cannabis sativa L. (marijuana). It has also been produced chemically as described in U.S. Pat. No. 3,668,224. Dronabinol is a light-yellow resinous oil that is sticky at room temperature, but hardens upon refrigeration. It turns to a flowable liquid when heated at higher temperatures. Dronabinol is insoluble in water. It has a pKa of 10.6 and an octanol-water partition coefficient: 6,000: 1 at pH 7. Dronabinol is available in natural (extracted from plant) and synthetic forms.
  • synthetic dronabinol may be utilized and may be synthesized using the starting materials Olivetol and p-2,8-menthadien-2-ol (PMD).
  • PMD p-2,8-menthadien-2-ol
  • the term "dronabinol” is further meant to encompass naturally occurring dronabinol, metabolites, synthetically derived dronabinol, and synthetically modified dronabinol.
  • the active ingredient comprises or consists essentially of Delta-9-tetrahydrocannabinol, also known as (and referred to herein as) dronabinol.
  • the cannabinoid comprises dronabinol hemisuccinate ester (THC-HS).
  • Cannabinoids such as dronabinol may be used alone or in combination with other cannabinoids or cannabis-derived molecules (synthetic or natural) or other medications in the formulations of the present invention.
  • the formulations and methods of the invention may further include one or more additional therapeutically active agents, such as, for example, non-narcotic analgesics such as acetaminophen or aspirin, opioid or opiate analgesics, non-steroidal anti-inflammatory drugs (NSAIDs, for example, non-selective cyclooxygenase inhibitors and COX-2 inhibitors), anti-emetics (for example, 5- hydroxytryptamine3 (5-HT3) inhibitors such as ondansetron, granisetron, tropisetron, palonosetron, dolasetron, and mirtazapine) and steroids (for example megestrol acetate, oxandrolone, oxymetholone, and dexamethasone).
  • a second therapeutically active drug including but not limited to the above-mentioned drugs, is incorporated into the oral cannabinoid dosage form.
  • the second therapeutically active drug is separately administered to the patient in conjunction with the oral cannabinoid dosage form.
  • the therapeutic compounds that make up the combination therapy may also be administered sequentially, with either therapeutic compound being administered by a regimen calling for two-step administration.
  • a regimen may call for sequential administration of the therapeutic compounds with spaced-apart administration of the separate, active agents.
  • the time period between the multiple administration steps may range from, for example, a few minutes to several hours to days, depending upon the properties of each therapeutic compound such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the therapeutic compound, as well as depending upon the effect of food ingestion and the age and condition of the subject.
  • Orcadian variation of the target molecule concentration may also determine the optimal dose interval.
  • the therapeutic compounds of the combined therapy may involve a regimen calling for administration of one therapeutic compound by oral route and another therapeutic compound by an oral route, a percutaneous route, an intravenous route, an intramuscular route, or by direct absorption through mucous membrane tissues.
  • a regimen calling for administration of one therapeutic compound by oral route and another therapeutic compound by an oral route, a percutaneous route, an intravenous route, an intramuscular route, or by direct absorption through mucous membrane tissues may involve a regimen calling for administration of one therapeutic compound by oral route and another therapeutic compound by an oral route, a percutaneous route, an intravenous route, an intramuscular route, or by direct absorption through mucous membrane tissues.
  • each such therapeutic compound will be contained in a suitable pharmaceutical formulation of pharmaceutically-acceptable excipients, diluents or other formulations components.
  • the formulations of the invention may be administered by a delivery route selected from the group consisting of: pulmonary, oral, nasal, transmucosal (eg. buccal and sublingual), transdermal, intravenous and ophthalmic.
  • pulmonary, oral, nasal, transmucosal (eg. buccal and sublingual), transdermal, intravenous and ophthalmic are preferably administered orally, e.g. via oral solution or sublingually.
  • the stabilized aqueous-based cannabinoid formulations of the present invention are not limited to administration by these routes, and can be administered via the nasogastric route, an intramuscular route, or by direct absorption through mucous membrane tissues, pulmonary, intravenous; transdermal, and ophthalmic administration as well as vaginal, rectal, parenteral or transmucosal (e.g., buccal or sublingual) administration.
  • the dosage form can be converted from a solution to a suspension, emulsion, suppository, spray, aerosol, gel, drops, syrup, elixir, or other dosage form, as desired.
  • the stable formulation of the present invention comprises therapeutic compound or mixture of therapeutic compounds, preferably dronabinol, water buffered to a pH from about 6 to about 7.5, a solvent which is preferably alcohol, a co-solvent such as propylene glycol, an antioxidant such as butylated hydroxyanisole, wherein the formulation does not use polyethylene glycol, and wherein the formulation is stable at 5 °C, for at least 6 to 12 months and/or; 25 °C /60% RH for at least 6 months; and/or 40 °C/75% RH for at least 3 to 6 months.
  • a solvent which is preferably alcohol, a co-solvent such as propylene glycol, an antioxidant such as butylated hydroxyanisole, wherein the formulation does not use polyethylene glycol, and wherein the formulation is stable at 5 °C, for at least 6 to 12 months and/or; 25 °C /60% RH for at least 6 months; and/or 40 °C/75% RH for at least 3 to 6 months
  • compositions described as part of the invention may also be incorporated into any of the compositions described as part of the invention.
  • the amount of each of these components which may be used will be optimized for each formulation, in order to obtain a stable product (dosage form) having the desired shelf-life.
  • the solvents are organic solvents such as dehydrated alcohol, ethanol, propanol, isopropanol, propylene glycol, and combinations thereof that are pharmaceutically acceptable based on the desired formulation.
  • dehydrated alcohol is used interchangeably with the term “absolute alcohol”.
  • the amount of dehydrated alcohol in a particular formulation will vary based on the intended formulation and the solubility of the cannabinoid.
  • the amount of dehydrated alcohol in the formulations of the present invention can range from about 10% to about 90%; from about 15% to about 65%; and about 15% to about 50% by weight.
  • the formulation contains co-solvent from about 1% to about 50% by weight propylene glycol and preferably from about 1% to about 10% by weight propylene glycol. Most preferably, the co-solvent will range from 3-10% by weight. In certain embodiments, the formulation of the present invention avoid the use of multiple cosolvent. In certain embodiments, the formulation uses only propylene glycol as a cosolvent.
  • solubilizing agents include Capryol 90; Cremophor RH40; Labrafil M 1944 CS; Labrafil M 2125 CS; Lauroglycol 90; PEG MW>4000; Plurol Oleique CC 497; poloxamer 124; poloxamer 188; Softigen 701; Softigen 767; Tagat TO; Tween 80; triacetin; triethylcitrate; tributyl citrate; acetyl triethylcitrate; acetyl tributyl citrate; ethyl oleate; ethyl caprylate; ethyl butyrate; triacetin; 2-pyrrolidone; 2-piperidone; N-methylpyrrolidone; N- ethylpyrrolidone; N-hydroxyethyl pyrrolidone; N-octylpyr
  • the formulations of the present invention may comprise a solubilizing agent from about 0 % to about 100%) of the inactive ingredients or from about 5% to about 85% by weight.
  • the formulation contains amounts of one or more pharmaceutically acceptable anti-oxidants in an amount effective to stabilize the cannabinoid contained therein such that the cannabinoid does not degrade to an unacceptable extent and the formulation is deemed stable for at least eighteen months when placed under storage conditions selected from refrigerated or room temperature.
  • an effective (stabilizing) amount of one or more pharmaceutically acceptable antioxidants may be added to the formulation.
  • antioxidant is used herein to describe any compound or combination of compounds that prevents or slows down cannabinoid oxidation.
  • anti-oxidants may be used, including but not limited to antioxidants such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, lecithin, Vitamin E tocopherol, sesamin, sesamol, sesamolin, alpha tocopherol, ascorbic acid, ascorbyl palmitate, fumaric acid, malic acid, sodium ascorbate and sodium metabi sulphite, as well as chelating agents such as disodium EDTA, may also be used to stabilize the cannabinoid formulations of the present invention.
  • the preparation may also contain anti-oxidant synergists to prevent oxidative degradation.
  • any of the known antioxidant synergists may also be used in effective amounts, for example disodium edetate.
  • the amount of anti-oxidant which may be used will be optimized for each formulation, in order to obtain a stable product (dosage form) having the desired shelf-life.
  • suitable formulations may include from about 0.001% to about 20% w/w of a pharmaceutically acceptable anti-oxidant(s).
  • BHA, or BHT or combinations thereof is used as the anti-oxidant in an amount of from about 0.001 to about 1%, w/w, and in certain embodiments more preferably in the range from about 0.01% to about 0.1% w/w.
  • the anti-oxidant preferably prevents the formation of degradants in the dosage form to unacceptable levels.
  • Preservatives have bactericidal and fungicidal properties.
  • Parabens are widely used preservatives in the pharmaceutical industry because of their efficacy as preservatives in combination with their long history of safe use. Parabens work best when they are used in combination since various combinations of parabens allows for the use of lower levels while increasing preservative activity. Examples of parabens include methyl paraben and propyl paraben.
  • the oral formulations of the present invention are free from any preservative.
  • the formulations of the invention may additionally include physiologically acceptable components such as sodium chloride and like materials conventionally used to achieve isotonicity with typical body fluids.
  • the formulations of the present invention contain at least about 40% w/w or more of water buffered to a pH of 6-7.5.
  • Agents which buffer the pH to maintain a physiologically compatible pH range to enhance the solubility and stability of the active agent present, and the like may also be included in certain embodiments of the present invention.
  • Suitable buffers include, but are not limited to acetate, bicarbonate, citrate, phosphate, pharmaceutically acceptable salts thereof and combinations or mixtures thereof.
  • one or more buffers When one or more buffers are utilized in the formulations of the invention, they may be combined, e.g., with a pharmaceutically acceptable vehicle and may be present in the final formulation, e.g., in an amount ranging from about 0.01% to about 20% by weight, more preferably from about 0.01% to about 10% by weight. Therefore, from about 5 mM to about 100 mM concentration of a buffer may be present in the formulations, more preferably from about 5 mM to about 50 mM concentration of a buffer may be present in the formulations
  • the concentration of buffer is such that a pH of the formulation is from about 5 to about 10; preferably from about 6 to about 8; more preferably from about 6.5 to about 7.5 and most preferably about 7.
  • the current formulation contains a mixture of sodium phosphate monobasic anhydrous, and sodium phosphate dibasic heptahydrate to form a buffering system with a 10 mM concentration and a pH of 7.
  • the invention is directed to stable dronabinol formulations that contain sucrose, fructose, sucralose, sorbitol, xylitol, saccharin, saccharin sodium, or combinations thereof as a sweetening agent.
  • the oral dronabinol formulations contain a pharmaceutically acceptable sweetener such as sucralose in an amount from about 0.01% to about 10% by weight.
  • Other exemplary embodiments may include sweeteners such as xylitol from about 1% to about 25%, saccharin from about 0.01%) to about 5%), and saccharin sodium from about 0.01% to about 5% by weight of the formulation.
  • the composition of the invention may be formulated by blending the dronabinol which has been dissolved in the solvent such as ethanol with the excipient solution.
  • the excipient solution may contain excipients such as ethanol, propylene glycol, sucralose, and BHA. It is degassed with nitrogen prior to adding the dissolved dronabinol. Then a pre-made buffer solution with a pH ranging from 6 to 7.5, such as for example, a sodium phosphate buffer is blended into the formulation.
  • the final oral dronabinol formulation is then filtered and filled into pharmaceutically acceptable single-dose or multi-dose containers
  • An exemplary formulation of the cannabinoid formulation of the present invention is as follows:
  • a container is flushed with nitrogen gas for about 15-20 minutes.
  • the container is air tight and remains under an inert atmosphere for the duration of the experiment.
  • An excipient solution is prepared by dissolving sucralose in a portion of dehydrated ethanol. Once a clear solution is obtained, propylene glycol and butylated hydroxyanisole are added. The excipient solution is sparged with nitrogen for 20-30 minutes.
  • a calculated amount of dronabinol is added to the excipient solution.
  • a pre-made buffer solution with a pH of about 7 is blended into the formulation. The solution is sparged with nitrogen for 20-30 minutes. Then water and the remaining dehydrated alcohol are added. The solution is stirred for 30 minutes.
  • the formulation is filtered and stored in an amber glass bottle.
  • Table 2 includes stability data for the oral dronabinol formulation prepared in Table 1.
  • the oral dronabinol formulation of the present invention was stored at 5 degrees C. and 25 degrees C, and assay and impurities were measured for up to twelve months. As can be seen from the results, the oral dronabinol formulation of the present invention remains within 80% of the dronabinol at all temperatures.
  • Table 3 contains one additional exemplary formulation of the dronabinol formulation of the present invention while Table 4 shows stability data of the said formulation.
  • Table 4 includes stability data for the dronabinol formulation of the present invention.
  • the dronabinol formulation of the present invention was stored at 5 degrees C, 25 degrees C, and 40 degrees C. and assay and impurities were measured for 6 months. As can be seen from the results, the dronabinol formulation of the present invention remains within 80% of the dronabinol at all temperatures.
  • Table 5 contains one additional exemplary formulation of the dronabinol formulation of the present invention while Table 6 shows stability data of the said formulation.
  • Table 6 includes stability data for the dronabinol formulation of the present invention.
  • the dronabinol formulation of the present invention was stored at 5 degrees C, 25 degrees C, and 40 degrees C. and assay and impurities were measured for 6 months. As can be seen from the results, the dronabinol formulation of the present invention remains within 90% of the dronabinol at all temperatures and total impurities were less than 4%.
  • Table 7 contains one additional exemplary formulation of the dronabinol formulation of the present invention while Table 8 shows stability data of the said formulation.
  • Table 8 includes stability data for the dronabinol formulation of the present invention.
  • the dronabinol formulation of the present invention was stored at 5 degrees C, 25 degrees C, and 40 degrees C. and assay and impurities were measured for 12 months. As can be seen from the results, the oral dronabinol solution of the present invention remains within 90% of the dronabinol at all temperatures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique stable comprenant d'environ 0,1 à environ 5 % p/p de dronabinol, au moins environ 40 % p/p ou plus d'eau tamponnée à un pH d'environ 6 à environ 7,5, d'environ 15 à environ 65 % p/p d'alcool, d'environ 3 à environ 10 % p/p de propylène glycol, d'environ 0,001 à environ 1 % p/p d'hydroxyanisole butylé, la formulation n'utilisant pas de polyéthylène glycol, et la formulation étant stable à une température de 5 °C pendant au moins 6 à 12 mois et/ou; à 25 °C/60 % RH pendant au moins 6 mois; et/ou à 40 °C/75 % RH pendant au moins 3 à 6 mois.
PCT/IN2018/050117 2017-03-10 2018-03-05 Formulations de dronabinol stables Ceased WO2018163202A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721008403 2017-03-10
IN201721008403 2017-03-10

Publications (1)

Publication Number Publication Date
WO2018163202A1 true WO2018163202A1 (fr) 2018-09-13

Family

ID=63448525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2018/050117 Ceased WO2018163202A1 (fr) 2017-03-10 2018-03-05 Formulations de dronabinol stables

Country Status (1)

Country Link
WO (1) WO2018163202A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations

Similar Documents

Publication Publication Date Title
US9345771B2 (en) Oral cannabinoid formulations
US8222292B2 (en) Liquid cannabinoid formulations
US20230038423A1 (en) Oral cannabinoid formulations
KR100514963B1 (ko) 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물
US8980940B2 (en) Stable cannabinoid compositions and methods for making and storing them
US20040110828A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
CN103237446B (zh) 含有抗微生物剂的氯维地平乳剂制剂
US20110097283A1 (en) Chewing gum compositions comprising cannabinoids
US20090181080A1 (en) Oral cannabinnoid liquid formulations and methods of treatment
EP3478267A1 (fr) Formulations orales de cannabinoïdes
JP5453096B2 (ja) （−）−δ９−トランス−テトラヒドロカンナビノールを含んでなる組成物
EA035750B1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
BRPI0715328A2 (pt) formulaÇço, e, dispositivo de dose unitÁria ou de dose méltipla para a administraÇço sublingual de uma droga
MX2007014862A (es) Composiciones inyectables y procedimiento para la preparacion de dichas composiciones.
US20080159961A1 (en) Pharmaceutical Composition
JP2017514924A (ja) シクロホスファミド液状濃縮物の製剤
US11253472B2 (en) Oral cannabinoid formulations
WO2020178725A1 (fr) Composition liquide stable de cyclophosphamide
US20110038899A1 (en) Pharmaceutical Solutions and Method for Solublilizing Therapeutic Agents
WO2018163202A1 (fr) Formulations de dronabinol stables
US10265293B2 (en) Oral cannabinoid formulations
US20180318214A1 (en) Pharmaceutical compositions of dronabinol
US20220160626A1 (en) Oral Cannabinoid Formulations
US20220273611A1 (en) Oronasal cbd formulations and uses thereof
US20250025416A1 (en) A formulation for an effective oral administration of ciclopirox with no adversal gastrointestinal toxicity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18764490

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18764490

Country of ref document: EP

Kind code of ref document: A1